The biosynthesis company CB Therapeutics has named Tiffany Hurd as its new business development lead.
At Carlsbad, California-based CB Therapeutics, Hurd will help forge partnerships with organizations that will benefit the company’s sustainability, value propositions and longevity.
Hurd has more than 14 years of experience working in senior neurology and neuroscience positions at Fortune 500 companies and more than four years of experience working with consulting teams, psychedelic companies and coaching individual clients.
CB Therapeutics partners with companies in the psychedelic, cannabinoid and food tech industries on the creation of biosynthetic compounds.
A press release from the company notes that Hurd will help build a bridge between the traditional pharmaceutical market and the nascent psychedelic drug discovery market.
“I think there’s so much opportunity for the company to continue to grow in many different ways,” Hurd said in a press statement. “I can even see a space where, you know, I’m coming in as the first business development lead and, and then, you know, over time developing and leading a team.”
Filed Under: Drug Discovery and Development
